Galectin-3 Levels and Heart Failure Prognosis
Author Information
Author(s): Rudolf A de Boer, Dirk J A Lok, Tiny Jaarsma, Peter van der Meer, Adriaan A Voors, Hans L Hillege, Dirk J van Veldhuisen
Primary Institution: University Medical Centre Groningen
Hypothesis
The study investigates the prognostic value of baseline galectin-3 levels in heart failure patients with both reduced and preserved ejection fraction.
Conclusion
Galectin-3 is an independent marker for outcome in heart failure and is particularly useful in patients with preserved ejection fraction.
Supporting Evidence
- A doubling of galectin-3 levels was associated with a hazard ratio of 1.97 for the primary outcome.
- Galectin-3 levels were correlated with higher IL-6 and CRP levels.
- The predictive value of galectin-3 was stronger in patients with preserved LVEF compared to those with reduced LVEF.
Takeaway
Galectin-3 is a blood marker that helps doctors understand how serious heart failure is, especially in older patients whose hearts still pump well.
Methodology
The study followed 592 hospitalized heart failure patients for 18 months, measuring baseline galectin-3 levels and comparing them to other biomarkers.
Limitations
The study's findings are limited by the small number of patients with preserved ejection fraction and the lack of standardized echocardiographic evaluation.
Participant Demographics
Mean age was 72 years, with 65% male; half were in NYHA class III and IV.
Statistical Information
P-Value
<0.001
Confidence Interval
1.62–2.42
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website